ArticleEuropean journal of neurology2025
Glymphatic Function in Prodromal Parkinson's Disease: Associations With Symptoms, Gray Matter Volume, and Phenoconversion Risk.
Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Alterations in the DTI-ALPS index and choroid plexus volume are associated with symptom severity in children with tic disorders.BMC neurology · 2026Article
- Brain endothelial homeostasis in psychiatric disorders: mechanisms, evidence, and translational opportunities.Frontiers in cellular neuroscience · 2026Review
- Glymphatic Function in Prodromal Parkinson's Disease: Associations With Symptoms, Gray Matter Volume, and Phenoconversion Risk.European journal of neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
BACKGROUND AND
objectivesGlymphatic dysfunction occurs in Parkinson's disease (PD), but its status in prodromal PD (pPD) is unclear. Using the diffusion tensor imaging along perivascular spaces (DTI-ALPS) index as an indirect proxy, this study aims to evaluate glymphatic-related changes in a pPD cohort and to explore their relationship with symptoms, gray matter volume, and risk of phenoconversion.
methodsWe analyzed data from the Parkinson's Progression Marker Initiative, including 51 healthy controls (HC), 83 individuals with pPD, and 202 with de novo PD (dnPD). The pPD cohort underwent ≥ 4-year follow-up. Cross-sectional analyses compared the DTI-ALPS index across three groups and examined associations between the DTI-ALPS index and clinical features/gray matter volume in the pPD cohort. For longitudinal analysis, the relationship of DTI-ALPS index with the risk of phenoconversion was assessed via Kaplan-Meier and Cox regression.
resultsDTI-ALPS index was significantly reduced in pPD and dnPD vs. HC (p < 0.001). In pPD, lower DTI-ALPS index correlated with: higher anxiety (STAI: r = -0.46, p = 0.02), elevated CSF p-tau (r = 0.52, p = 0.04) and t-tau (r = 0.42, p = 0.03), lower volumes of right temporal pole (p = 0.03), left thalamus (p = 0.01), right superior occipital gyrus (p = 0.04), and higher volume of left posterior central gyrus (p = 0.03). Among 83 pPD subjects, 10 phenoconverted to PD. Each standard deviation decrease in DTI-ALPS increased conversion risk by 13% (adjusted HR = 0.87, 95% CI 0.83-0.92; p = 0.018).
conclusionReduced DTI-ALPS index in pPD-which may reflect altered glymphatic function-is associated with accelerated phenoconversion and correlates with clinical symptoms and cortico-thalamic structural changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.